Vestcor Inc Raises Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Vestcor Inc increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 20.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,458 shares of the biopharmaceutical company’s stock after buying an additional 420 shares during the period. Vestcor Inc’s holdings in Alnylam Pharmaceuticals were worth $676,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the stock. Eventide Asset Management LLC grew its position in shares of Alnylam Pharmaceuticals by 157.9% in the 3rd quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock worth $61,698,000 after buying an additional 137,333 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in Alnylam Pharmaceuticals by 11,433.4% in the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after acquiring an additional 135,829 shares in the last quarter. AQR Capital Management LLC grew its stake in Alnylam Pharmaceuticals by 92.5% during the 2nd quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock worth $65,862,000 after buying an additional 130,482 shares during the last quarter. Deerfield Management Company L.P. Series C acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $29,111,000. Finally, Avoro Capital Advisors LLC increased its stake in Alnylam Pharmaceuticals by 33.3% during the 2nd quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $97,200,000 after purchasing an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $245.26 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The firm has a market capitalization of $31.63 billion, a PE ratio of -93.61 and a beta of 0.32. The business has a 50 day simple moving average of $267.46 and a 200-day simple moving average of $247.48.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. The firm’s revenue was down 33.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.15 earnings per share. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the sale, the chief executive officer now directly owns 78,880 shares in the company, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Tolga Tanguler sold 1,469 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,370 shares of company stock worth $2,100,703. Insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on ALNY. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Canaccord Genuity Group boosted their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a report on Friday, November 1st. Barclays raised their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. HC Wainwright reiterated a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Finally, Scotiabank raised their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $298.09.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.